TGTX — TG Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.57bn
- $8.77bn
- $616.29m
U.S. STOCKS ON THE MOVE-Virgin Galactic, Meta Platforms, EchoStar
U.S. STOCKS ON THE MOVE-Palo Alto Networks, Masimo, Tigo Energy
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Home Depot, SMART Global
TG Therapeutics up on prelim sales of multiple sclerosis drug, 2024 view
Brief: Tg Therapeutics Provides Preliminary Q4 And Full Year 2023 Net Revenue
Precision BioSciences rises on license deal to develop cancer therapy
Brief: Precision Biosciences Completes License Deal With TG Therapeutics For Cell Therapy Azer-Cel
Brief: Tg Therapeutics Announces Global License Agreement With Precision Biosciences
TG Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: TG Therapeutics Q3 Net Income USD 113.93 Mln
U.S. STOCKS ON THE MOVE-Marriott, Advanced Micro Devices, Leidos Holdings
U.S. STOCKS ON THE MOVE-SiriusXM, ABVC Biopharma, Altria
TG Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
TG Therapeutics down on missing Q2 estimates
Brief: TG Therapeutics Q2 Product Revenue USD 16.036 Mln
Brief: TG Therapeutics, Neuraxpharm Announce Ex-US Commercialization Agreement For BRIUMVI
Brief: Tg Therapeutics Announces European Commission Approval For Briumvi® (Ublituximab-Xiiy) For The Treatment Of Relapsing Forms Of Multiple Sclerosis In Adults
Brief: Tg Therapeutics Announces Data From The Ultimate I & Ii Phase 3 Trials Of Briumvi® (Ublituximab-Xiiy) In Multiple Sclerosis To Be Presented At The 2023 Consortium Of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics gains on lower-than-expected Q1 loss, higher revenue